🟢 Harrow Health Inc is trading 6.6% higher after announcing the re-launch of its VKC treatment, VERKAZIA®

Harrow Health Inc is trading 6.6% higher at $35.65 after the company announced the re-launch of VERKAZIA®, a prescription therapy for the allergic eye disease vernal keratoconjunctivitis (VKC).

• The re-launch focuses on ensuring a dependable supply and removing access barriers for the treatment, which is primarily for a serious allergic eye disease affecting children.
• CEO Mark L. Baum noted that VERKAZIA is the second of three priority products in the company's portfolio that it is actively executing against.